Intervention

Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer

ClinicalTrials.gov intervention label

Clinical trials1

Recruiting0

Common conditions1

Lead sponsors shown1

Clinical trials

1 shown

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung CancerNCT03501056 · 2018-03-27

WITHDRAWN

Common conditions

Advanced Lung Cancer1

Leading sponsors

Fuda Cancer Hospital, Guangzhou1

Trial status mix

WITHDRAWN1

Phase mix

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.